Yahoo Finance analysis suggests Eli Lilly and Co (LLY) is a better healthcare stock buy for 2026 compared to AbbVie Inc (ABBV), citing Eli Lilly's strong growth in metabolic and obesity platforms driven by GLP-1 drugs. Eli Lilly's 2025 revenue reached nearly $65.2 billion, up 45%, with net income of approximately $20.6 billion. The company is projected to see 2026 revenue grow up to 30% to $85.2 billion, with net income close to $31 billion.

AbbVie, while a pharmaceutical giant in immunology and neuroscience, reported 2025 revenue of nearly $61.2 billion, up 8.7%, and net income of about $4.3 billion. It recently announced the acquisition of Apogee Therapeutics for approximately $10.9 billion to diversify its portfolio. AbbVie's net income is expected to surge to $14.6 billion in 2026, with sales reaching $67.2 billion, but it faces pressures from patent expirations and biosimilar compe